Herpes Simplex and Herpes Zoster Eye Disease

Edell, Aimée R. P.; Cohen, Elisabeth J.

doi:10.1097/icl.0b013e31829a3b47

Cited by 16 publications

(8 citation statements)

References 19 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We were unable to replicate previously reported risk factors including immunosuppression, female gender, older age, and absence of zoster vaccination. 8-10,13,31-34 The low numbers of females, immunosuppressed and vaccinated patients in our cohort may have limited our power to demonstrate differences in recurrence risk.…”

Section: Discussionmentioning

confidence: 99%

“…2-7 Immunosuppression and the immunosenescence of aging have been associated with an increased risk of developing HZ. 8-10 The most common long term complication of HZ is postherpetic neuralgia (PHN), or persistent neuropathic pain lasting beyond three months after initial presentation of HZ. PHN can negatively affect quality of life to a degree similar to congestive heart failure, depression, acute myocardial infarction, diabetes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology of Herpes Zoster Ophthalmicus

et al. 2016

View full text Add to dashboard Cite

Purpose A hospital-based epidemiology study to describe herpes zoster ophthalmicus (HZO) prevalence, and identify risk factors for recurrent and chronic disease. Design Retrospective, hospital-based cohort study Participants All patients evaluated in the Broward and Miami VA Healthcare System (MIAVHS) during the study period. Methods Retrospective medical record review of patients seen in the MIAVHS from January 1, 2010 and December 31, 2014 with a HZO clinical diagnosis. Assessment of the patient's clinical course was defined by the following: an acute episode of HZO was defined as quiescence of disease within 90 days of initial presentation; HZO recurrence was defined as any recurrent eye disease or rash >90 days after quiescence disease was noted off therapy; chronic HZO was defined as active disease persisting greater than 90 days from initial presentation. Main Outcome Measures 1) Frequency of HZ involving the V1 dermatome (HZO) with and without eye involvement; 2) HZO recurrence rates 3) Risk factors for recurrent or chronic HZO. Results 90 patients with HZO were included in the study. The mean age at incident episode of HZO was 68±13.8 years (range, 27-95 years). The majority of patients were white (73%), immune competent (79%), and did not receive zoster vaccination at any time point in their follow up (82%). Patients were followed for a mean of 3.9±5.9 years, (range, 0-33 years). The period prevalence of HZ in any dermatome was 1.1%, the frequency of HZ involving V1 (HZO) was 0.07% and the frequency of HZO with eye involvement was 0.05%. The overall 1, 3, and 5-year recurrence rates for either recurrent eye disease or rash were 8%, 17%, 25%, respectively. Ocular hypertension (HR 4.6, 95% Cl 1.3-16.5; OR 6.7, 95% Cl 1.5-31.2) and uveitis (HR 5.7, 95%CI 1.7-19.0; OR 6.7, 95% C1 1.5-31.2) increased the risk of recurrent and chronic disease. Conclusion This study supports newer data that a significant proportion of patients experience recurrent and chronic HZO. Further study is needed to guide preventative and therapeutic approaches to recurrent and chronic HZO.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Epidemiology of Herpes Zoster Ophthalmicus

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Available prevention modalities, such as the vaccine against herpes zoster and long-term oral antiviral therapy to reduce ocular HSV infection recurrence, were underused. 7 It's equally important to do a comprehensive examination of eye and all other systems to rule out their afflictions. 8,9,10,11 Our findings were in harmony with the findings of previous authors.…”

Section: Discussionmentioning

confidence: 99%

“…8,9,10,11 Our findings were in harmony with the findings of previous authors. 3,7,2 We suggest that a larger study be conducted to get a more satistically and clinically sound outcome.…”

Section: Discussionmentioning

confidence: 99%

A Clinical Study on Natural History of Viral Keratitis

Srinivas¹,

Naidu²

2015

jebmh

View full text Add to dashboard Cite

We conducted a prospective case study in patients attending outpatient department of ophthalmology, in Kakinada govt. general Hospital during the period of September 2013 to August 2015. The study was done in 54 eyes of 50 patients in order to evaluate the natural history of Viral keratitis.We came to the conclusion that most of the clinical features are in accordance with the previous studies, and oral acyclovir has some curative and prophylactic properties in few selected cases.

show abstract

“…A significant fraction of HZ patients develop difficult-to-treat chronic pain states termed post-herpetic neuralgia (PHN), which can be so severe that they reduce quality-of-life. HZ may also be followed by neurological, gastrointestinal, and vascular diseases [2][3][4], as well as potentially blinding complications that develop after facial zoster [5].…”

Section: Introductionmentioning

confidence: 99%

Antiviral Targeting of Varicella Zoster Virus Replication and Neuronal Reactivation Using CRISPR/Cas9 Cleavage of the Duplicated Open Reading Frames 62/71

Yee

Goldstein

et al. 2022

Viruses

View full text Add to dashboard Cite

Varicella Zoster Virus (VZV) causes Herpes Zoster (HZ), a common debilitating and complicated disease affecting up to a third of unvaccinated populations. Novel antiviral treatments for VZV reactivation and HZ are still in need. Here, we evaluated the potential of targeting the replicating and reactivating VZV genome using Clustered Regularly Interspaced Short Palindromic Repeat-Cas9 nucleases (CRISPR/Cas9) delivered by adeno-associated virus (AAV) vectors. After AAV serotype and guide RNA (gRNA) optimization, we report that a single treatment with AAV2-expressing Staphylococcus aureus CRISPR/Cas9 (saCas9) with gRNA to the duplicated and essential VZV genes ORF62/71 (AAV2-62gRsaCas9) greatly reduced VZV progeny yield and cell-to-cell spread in representative epithelial cells and in lytically infected human embryonic stem cell (hESC)-derived neurons. In contrast, AAV2-62gRsaCas9 did not reduce the replication of a recombinant virus mutated in the ORF62 targeted sequence, establishing that antiviral effects were a consequence of VZV-genome targeting. Delivery to latently infected and reactivation-induced neuron cultures also greatly reduced infectious-virus production. These results demonstrate the potential of AAV-delivered genome editors to limit VZV productive replication in epithelial cells, infected human neurons, and upon reactivation. The approach could be developed into a strategy for the treatment of VZV disease and virus spread in HZ.

show abstract

Herpes Simplex and Herpes Zoster Eye Disease

Cited by 16 publications

References 19 publications

Epidemiology of Herpes Zoster Ophthalmicus

Epidemiology of Herpes Zoster Ophthalmicus

A Clinical Study on Natural History of Viral Keratitis

Antiviral Targeting of Varicella Zoster Virus Replication and Neuronal Reactivation Using CRISPR/Cas9 Cleavage of the Duplicated Open Reading Frames 62/71

Contact Info

Product

Resources

About